Cargando…

Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report

Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Cheol Kyu, Hur, Jae Young, Choi, Chang-Min, Kim, Tae-Ok, Cho, Hyun-Ju, Shin, Hong-Joon, Lim, Jung-Hwan, Choi, Yoo-Duk, Kim, Young-Chul, Oh, In-Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729642/ https://www.ncbi.nlm.nih.gov/pubmed/29215816 http://dx.doi.org/10.3346/jkms.2018.33.e7

Ejemplares similares

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
por: Park, Cheol-Kyu, et al.
Publicado: (2021)

Potentially fatal complications of systemic air embolism after computed tomography‐guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report
por: Oh, Hyung‐Joo, et al.
Publicado: (2020)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
por: Yoon, Joon‐Young, et al.
Publicado: (2019)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
por: Park, Cheol‐Kyu, et al.
Publicado: (2020)

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Delayed diagnosis of lung cancer due to misdiagnosis as worsening of sarcoidosis: a case report
por: Shin, Hong-Joon, et al.
Publicado: (2020)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
por: Park, Ha-Young, et al.
Publicado: (2019)

Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer
por: Kim, Tae‐Ok, et al.
Publicado: (2018)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
por: Yoon, Seong-Hoon, et al.
Publicado: (2015)

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
por: Park, Seongho, et al.
Publicado: (2019)

Pulmonary sclerosing pneumocytoma mimicking lung cancer: Case report and review of the literature
por: Lim, Jung‐Hwan, et al.
Publicado: (2016)

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
por: Kim, Taeyun, et al.
Publicado: (2021)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
por: Yoo, Sang Hoon, et al.
Publicado: (2016)

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations
por: Kim, In Ae, et al.
Publicado: (2021)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
por: Shi, Yuequan, et al.
Publicado: (2018)

The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA insertion: a case report
por: He, Yueming, et al.
Publicado: (2022)

Microbiological Characteristics and Predictive Factors for Mortality in Pleural Infection: A Single-Center Cohort Study in Korea
por: Park, Cheol-Kyu, et al.
Publicado: (2016)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature
por: Kang, Hyun-Wook, et al.
Publicado: (2016)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Incidence of Cholangiocarcinoma with or without Previous Resection of Liver for Hepatolithiasis
por: Lee, Joon Young, et al.
Publicado: (2013)

Pulmonary epithelioid hemangioendothelioma misdiagnosed as a benign nodule
por: Kim, Minah, et al.
Publicado: (2015)

Risk factors for cerebral complications in patients with pulmonary arteriovenous malformations: A multicenter retrospective cohort study
por: Na, Young-Ok, et al.
Publicado: (2022)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

A Case of Pulmonary Alveolar Microlithiasis
por: Kang, Hyun Wook, et al.
Publicado: (2011)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report
por: Gao, Yan, et al.
Publicado: (2018)

Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report
por: Lin, Ling, et al.
Publicado: (2019)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

Three cases of rigid bronchoscopic removal of carinal masses: Case report
por: Lee, Jae-Kyeong, et al.
Publicado: (2022)

Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness
por: Kim, Tae-Ok, et al.
Publicado: (2021)

Validation of Previous Spirometric Reference Equations and New Equations
por: Choi, Hye Sook, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c5v2t8295bootjfco6ln7fooup